Depomed (DEPO) Misses Q2 EPS by 1c, Trims FY Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/7/2026
- Wall St futures fall as yields and oil rebound; Fed minutes in focus
- Want to be a stock market bear? BCA says watch potential U.S. tax increases
- SpaceX seeks $40bn in financing for Nvidia chip purchase
- Musk rules out TSMC role in Terafab operations; Intel gains
- U.S. 10-year yield climb revives dotcom-era parallels: UBS weighs in
- HubSpot to cut 7% of workforce in restructuring plan
- Emera and Canadian Utilities agree to merge in $72B all-share deal
- Caribou Biosciences to halt CAR-T programs, explore sale
- Stryker names Spencer Stiles as CEO, Lobo moves to chair
- S&P 500, Nasdaq reach record closing highs as focus pivots to earnings
DepoMed Inc (DEPO) PT Lowered to $9 at Piper Jaffray
August 8, 2017 8:23 AM EDTPiper Jaffray lowered its price target on DepoMed Inc (NASDAQ: DEPO) to $9.00 (from $10.00) while maintaining a Neutral rating following Q2 results and another downward guide.
"Notably, DEPO cut its 2017 revenue and EBITDA guidance ranges once again, driven in part by continued headwinds... More



